This multibagger pharma stock is down 10% from record high—CFO reveals growth plan
- Sai Life Sciences CFO Sivaramakrishnan Chittor said progress continues in the China Plus One opportunity
- China Plus One demand could benefit Indian pharmaceutical services companies, including Sai Life Sciences